AstraZeneca disputes IRA’s orphan drug provisions in latest legal challenge to the law

As­traZeneca is the lat­est phar­ma com­pa­ny to chal­lenge the In­fla­tion Re­duc­tion Act in court, this time ze­ro­ing in on the law’s pro­vi­sions around or­phan drugs.

The com­pa­ny filed a com­plaint Fri­day in US Dis­trict Court for the Dis­trict of Delaware, ar­gu­ing that the drug price ne­go­ti­a­tion pro­vi­sions in the IRA “run head­long” in­to the Or­phan Drug Act, which was passed in 1983 and is in­tend­ed to en­cour­age com­pa­nies to in­vest in treat­ments for rare dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.